Celmatix Company

Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions. Their products include Polaris, Fertilome genetic test and MyFertility Compass. Celmatix's lead program aims to protect the ovary from chemotherapy-induced ovarian failure (CIOF). For the 1.9 million pre-menopausal women diagnosed with cancer, the need is critical, urgent, and unmet.

Headquarters: New York, New York, United States
Industry: Reproductive Health & Contraception
Employee Number: 11-50
Estimated Revenue: $10M to $50M
Investors Number: 7
Investment Stage: N/A
Investor Type: Company
Funding Status: Early Stage Venture
Number Of Exists: Venture - Series Unknown
Technology: Longevity FemTech
Last Funding Type: Venture - Series Unknown
Founded Date: 01-01-2009
Total Funding: $53,660,000
Last Funding Date: 2019-04-01